You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR INCIVEK


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Incivek

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT01511432 ↗ A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects Completed Vertex Pharmaceuticals Incorporated Phase 1 2012-01-01 The purpose of this study is to evaluate the relative bioavailability, safety, and tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Incivek

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01355289 ↗ Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501 Completed Eisai Inc. Phase 2 2011-11-01 To evaluate the efficacy of E5501 by measuring platelet response in subjects with chronic hepatitis C virus (HCV)-related thrombocytopenia who require antiviral treatment.
NCT01459913 ↗ Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype Terminated Vertex Pharmaceuticals Incorporated Phase 3 2011-11-01 The purpose of this study is to evaluate if a 12-week total regimen of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV) (T12/PR12) is safe and effective in subjects who have the interleukin-28B (IL28B) CC genotype. The subjects enrolled in this study will have chronic hepatitis C virus (HCV) infection and will not have cirrhosis of the liver.
NCT01511432 ↗ A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects Completed Vertex Pharmaceuticals Incorporated Phase 1 2012-01-01 The purpose of this study is to evaluate the relative bioavailability, safety, and tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.
NCT01581138 ↗ VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C Completed Vertex Pharmaceuticals Incorporated Phase 2 2012-07-01 The purpose of this study is to evaluate the efficacy and safety of two all oral regimens in subjects who have chronic hepatitis C and have not received treatment yet.
NCT01592006 ↗ Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients Terminated University of Chicago Phase 4 2012-04-01 Patients are being asked to be part of this study because they are a liver transplant recipient and have the Hepatitis C Virus (HCV). Current routine treatment for HCV for liver transplant patients includes taking two medications called pegylated interferon alfa-2a (Pegasys®) and ribavirin. Patients Pegasys and ribavirin are FDA approved for the treatment of HCV. This study will evaluate the safety and efficacy of adding a third drug called telaprevir for the experimental treatment of HCV in liver transplant patients. The combination of Pegasys, ribavirin and telaprevir is currently FDA approved for the treatment of HCV, but is specifically not FDA approved for HCV patients who have had a liver transplant. This is because more information is needed about possible drug interactions between telaprevir and cyclosporine, or telaprevir and tacrolimus-based immunosuppressive drugs, which are typically part of routine care for transplant patients. Studies have shown that the addition of telaprevir greatly increases the efficacy of Pegasys and ribavirin for the treatment of HCV. However, these studies did not include adequate information on transplant patients due to the potential drug interactions. The investigators hope to gather more information about the safety and efficacy of telaprevir given in combination with Pegasys and ribavirin in the liver transplant patients who have HCV that is not well controlled with Pegasys and ribavirin alone.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Incivek

Condition Name

Condition Name for Incivek
Intervention Trials
Hepatitis C 3
Hepatitis C, Chronic 3
Chronic Hepatitis C 2
Chronic Hepatitis C Virus 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Incivek
Intervention Trials
Hepatitis C 11
Hepatitis 10
Hepatitis A 7
Hepatitis C, Chronic 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Incivek

Trials by Country

Trials by Country for Incivek
Location Trials
United States 60
Canada 8
Brazil 5
Israel 2
Russian Federation 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Incivek
Location Trials
Texas 6
California 5
Virginia 4
Georgia 3
Florida 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Incivek

Clinical Trial Phase

Clinical Trial Phase for Incivek
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Incivek
Clinical Trial Phase Trials
Completed 6
Terminated 3
Withdrawn 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Incivek

Sponsor Name

Sponsor Name for Incivek
Sponsor Trials
Vertex Pharmaceuticals Incorporated 5
Santaris Pharma A/S 2
Eisai Inc. 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Incivek
Sponsor Trials
Industry 9
Other 4
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.